CD70: An emerging target in cancer immunotherapy

J Jacobs; V Deschoolmeester; K Zwaenepoel; C Rolfo; K Silence; S Rottey; F Lardon; E Smits; P Pauwels

doi:10.1016/j.pharmthera.2015.07.007

CD70: An emerging target in cancer immunotherapy

Pharmacol Ther. 2015 Nov:155:1-10. doi: 10.1016/j.pharmthera.2015.07.007. Epub 2015 Jul 26.

Authors

J Jacobs¹, V Deschoolmeester², K Zwaenepoel³, C Rolfo⁴, K Silence⁵, S Rottey⁶, F Lardon⁷, E Smits⁸, P Pauwels²

Affiliations

¹ Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium. Electronic address: julie.jacobs@uantwerpen.be.
² Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
³ Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
⁴ Department of Oncology, Antwerp University Hospital, Edegem, Belgium; Phase 1-Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium.
⁵ arGEN-X BVBA, Ghent, Belgium.
⁶ Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
⁷ Center for Oncological Research, University of Antwerp, Wilrijk, Belgium.
⁸ Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, Edegem, Belgium.

PMID: 26213107
DOI: 10.1016/j.pharmthera.2015.07.007

Abstract

Over the last decades, advances in the knowledge of immunology have led to the identification of immune checkpoints, reinvigorating cancer immunotherapy. Although normally restricted to activated T and B cells, constitutive expression of CD70 in tumor cells has been described. Moreover, CD70 is implicated in tumor cell and regulatory T cell survival through interaction with its ligand, CD27. In this review, we summarize the targetable expression patterns of CD70 in a wide range of malignancies and the promising mechanism of anti-CD70 therapy in stimulating the anti-tumor immune response. In addition, we will discuss clinical data and future combination strategies.

Keywords: CD27; CD70; Cancer immunotherapy; Combination therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
CD27 Ligand / immunology*
Humans
Immunotherapy*
Neoplasms / immunology
Neoplasms / therapy*

Substances

CD27 Ligand
CD70 protein, human